Trial Profile
The Pharmacokinetics and Safety of the Direct Acting Antiviral Regimen of ABT-450/r, Ombitasvir with/ without Dasabuvir in Subjects with Mild, Moderate and Severe Renal Impairment Compared to Subjects with Normal Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2015
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics
- Sponsors AbbVie
- 31 Aug 2015 New trial record